Press Release


Global BioLife's new mosquito repellent formula performs well against mosquitos in independent testing
Jun 12, 2019 14:00 JST
Singapore Exchange-listed Singapore eDevelopment Limited (Stock Code 40V) ("SeD") wishes to announce today that its U.S. biomedical subsidiary, Global BioLife Inc. ("Global BioLife"), has independently tested a new mosquito repellent formula which performs well against mosquitos for six (6) to eight (8) hours.
More info..

Singapore eDevelopment subsidiary Global BioLife's 3F Antimicrobial Fragrance shows Efficacy against Tuberculosis
Jan 28, 2019 12:00 JST
SGX-listed Singapore eDevelopment Ltd (SeD) is pleased to announce that its U.S. biomedical subsidiary Global BioLife Inc. has developed 3F Antimicrobial Fragrance, which shows efficacy against tuberculosis.
More info..

Singapore eDevelopment Subsidiary, Global BioLife, Proudly Announces Presentation of Parkinson's Research at Neuroscience 2018
Nov 07, 2018 19:00 JST
Singapore eDevelopment (SGX: 40V) ("SeD") subsidiary, Global BioLife Inc. is pleased to announce that research of their promising drug platform, Linebacker, will be presented at Neuroscience 2018, the Annual Meeting for the International Society for Neuroscience (SfN) in San Diego, California.
More info..

Singapore eDevelopment Announces Corporate and Business Update
Jun 18, 2018 19:00 JST
The Board of Directors of Singapore eDevelopment Limited wishes to provide shareholders an update on the Group's operations.
More info..

Singapore Exchange-Listed Singapore eDevelopment Limited's U.S. Biomedical Subsidiary Global BioLife, Inc. Develops Low Glycemic Modified Sugar
May 31, 2018 18:00 JST
Singapore Exchange-listed Singapore eDevelopment Limited ("SeD") announced today that its U.S. biomedical subsidiary, Global BioLife, Inc. ("Global BioLife"), has developed a low glycemic index, naturally modified sugar - Laetose - which has the potential to affect the world's sugar market.
More info..

Singapore eDevelopment biomedical subsidiary confirms LB2 efficacy against Ebola
Mar 01, 2018 14:00 JST
Singapore eDevelopment (SGX: 40V; SeD) is pleased to announce biomedical subsidiary Global BioLife, Inc. has completed the initial Zaire Ebola research portion for the study of new anti-viral drug LB2, part of its new universal therapeutic drug platform, Linebacker.
More info..

Singapore eDevelopment's Biomedical Subsidiary Confirms 100% Repellency of 3F Mosquito Fragrance
Nov 01, 2017 18:00 JST
Singapore Exchange-listed Singapore eDevelopment Limited ("SeD") announced today that its U.S. biomedical subsidiary, Global BioLife Inc. ("Global BioLife") has completed development and testing of mosquito deterring technologies including fragrances, paints, and fabric.
More info..

SGX-Listed Singapore eDevelopment's Global BioLife Inc Develops Breakthrough Modified Sugar
Oct 24, 2017 18:00 JST
SGX-listed Singapore eDevelopment Limited ("SeD") announced today that its U.S. biomedical subsidiary, Global BioLife Inc. ("Global BioLife"), has developed a breakthrough low-calorie, low glycemic index, natural, modified sugar Laetose -- which has the potential to affect the world's sugar market.
More info..

Singapore eDevelopment's Global BioLife and U.S.-based Chemia Corporation to Develop Functional Fragrances to Fight Mosquito-Borne Diseases
Aug 15, 2017 19:00 JST
Singapore eDevelopment Ltd (SeD; SGX:SGE) has announced that its indirect subsidiary, Global BioLife Inc., is collaborating with U.S.-based Chemia Corporation to develop specialised fragrances which can counter mosquito-borne diseases, diminish stress and anxiety, and act in anti-viral medical applications.
More info..

First-Year Performance of Global Systematic Multi-Strategy Fund
Jun 15, 2017 10:15 JST
The Board of Directors of Singapore eDevelopment Ltd ("SeD") wishes to announce that its Global Systematic Multi-Strategy Fund ("GSMS Fund") managed by Hengfai Asset Management Pte Ltd ("HFAM"), a wholly owned subsidiary of SeD's investment-arm SeD Capital Pte Ltd, achieved a gross and net return of 15% and 10%, respectively, in its first year of operation.
More info..

Singapore eDevelopment Subsidiary Initiates Research on New Universal Drug Platform
May 22, 2017 11:00 JST
Singapore eDevelopment Limited ("SeD"), through its subsidiary, Global BioLife Inc. ("Global BioLife") has initiated advanced research of a new universal therapeutic drug platform, known as Linebacker, to combat a range of diseases including Alzheimer's, diabetes and cancer.
More info..

Latest Release


More Latest Release >>